Cidofovir

SKU: orb1226931

Description

The prodrug of cidofovir diphosphate that inhibits cytomegalovirus (CMV) viral replication by selectively inhibiting viral DNA polymerases; also incorporates itself into viral DNA hence inhibiting viral DNA synthesis during reproduction.CMV Infection Approved(In Vitro):Cidofovir (5-100 μM, 72 hours) has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC50 of 11 μM, and can reduce Crandell-Reese feline kidney cell counts in a dose-dependent manner.Cidofovir (10-1000 μM, 24-120 hours) can reduce cancer cell viability and induces apoptosis.(In Vivo):Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 113852-37-2
• MW: 279.187
• Purity: >98% (HPLC)
• Formula: C₈H₁₄N₃O₆P
• SMILES: OC[C@@H](OCP(O)(O)=O)CN1C=CC(N)=NC1=O
• Target: CMV
• Solubility: H2O: 6.4 mg/mL (Need warming)

Bioactivity

• In Vivo:
  Cidofovir (subcutaneous injection, 100 mg/kg, 3-6 days interval, 21 days) is highly protective against death from cowpox virus (CPV) infection at high doses in female weanling BALB/c mice. Animal model: Female weanling BALB/c mice infected with cowpox virus (CPV). Dosage: 100 mg/kg. Administration: Subcutaneous injection; 3-6 days interval; 21 days. Result: Prevented 80-100% of mouse deaths when administered on the first 4-3 days before infection. Protected 35-50% of mice when administered on the fourth day after infection, and 10-20% when administered on the sixth day.
  Read more...
• In Vitro:
  Cidofovir (5-100 μM, 72 hours) has antiviral activity against feline herpesvirus type-1 (FHV-1) with an IC50 of 11 μM, and can reduce Crandell-Reese feline kidney cell counts in a dose-dependent manner. Cidofovir (10-1000 μM, 24-120 hours) can reduce cancer cell viability and induces apoptosis. Cell Cytotoxicity Assay Cell line: Crandell-Reese feline kidney(CRFK) cells. Concentration: 10-100 μM. Incubation time: 72 hours. Result: Reduced CRFK cells by 9.1%. Cell Viability Assay Cell line: Caco-2, FTC-133, HeLa, Hep-G2, MDA-MB-231, NCI-H1975 and PC-3 cells. Concentration: 10-1000 μM. Incubation time: 24, 48, 72, 96, 120 hours. Result: Resulted in a gradual decrease in tumor cell viability with time and concentration increasing and inhibited the number of FTC-133 cell clones by about 55% at 100 μM comparing to the untreated group. Apoptosis Analysis Cell line: FTC-133 cells. Concentration: 100 μM. Incubation time: 96 hours. Result: Showed a significant increase in the expression of pro-apoptotic proteins, such as cytochrome c, phospho-p53 (S15) and caspase-3 by 130%, 49%, and 46%, respectively while the anti-apoptotic protein Bcl-x decreased significantly by 57% comparing to the untreated cells.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

GS-0504 | HPMPC | (S)-HPMPC

Quick Database Links

Gene Symbol

CMV